Market closed
FRACTYL HEALTH/$GUTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About FRACTYL HEALTH
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Ticker
$GUTS
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
107
Website
FRACTYL HEALTH Metrics
BasicAdvanced
$74M
-
-$1.62
-
-
Price and volume
Market cap
$74M
52-week high
$7.89
52-week low
$0.87
Average daily volume
282K
Financial strength
Current ratio
3.629
Quick ratio
3.412
Long term debt to equity
202.449
Total debt to equity
219.885
Management effectiveness
Return on assets (TTM)
-63.44%
Return on equity (TTM)
1,476.02%
Valuation
Price to revenue (TTM)
707.26
Price to book
2.59
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
-0.977
Growth
Revenue change (TTM)
-22.50%
Earnings per share change (TTM)
-96.43%
3-year earnings per share growth (CAGR)
-61.62%
What the Analysts think about FRACTYL HEALTH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for FRACTYL HEALTH stock.
FRACTYL HEALTH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FRACTYL HEALTH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FRACTYL HEALTH News
AllArticlesVideos
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
GlobeNewsWire·3 days ago
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewsWire·1 week ago
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for FRACTYL HEALTH stock?
FRACTYL HEALTH (GUTS) has a market cap of $74M as of May 09, 2025.
What is the P/E ratio for FRACTYL HEALTH stock?
The price to earnings (P/E) ratio for FRACTYL HEALTH (GUTS) stock is 0 as of May 09, 2025.
Does FRACTYL HEALTH stock pay dividends?
No, FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next FRACTYL HEALTH dividend payment date?
FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders.
What is the beta indicator for FRACTYL HEALTH?
FRACTYL HEALTH (GUTS) does not currently have a Beta indicator.